NEW YORK — Canadian diagnostics firm MedMira said on Wednesday that it has received CE marking for its Vyra CoV2Flu Antigen Test, a combination assay for SARS-CoV-2 and influenza A and B.
The test uses the company's Rapid Vertical Flow technology, which enables the formation of specific antigen-antibody reactions for the capture of biomarkers in sample types. It is designed to detect the viruses in a single nasal swab sample.
In late 2022, MedMira received CE marking for the Vyra COVID-19 Antigen Test.